The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, ATAI Life Sciences N.V (NASDAQ: ATAI) closed at $5.28 down -1.31% from its previous closing price of $5.35. In other words, the price has decreased by -$1.31 from its previous closing price. On the day, 3.34 million shares were traded. ATAI stock price reached its highest trading level at $5.56 during the session, while it also had its lowest trading level at $5.17.
Ratios:
For a deeper understanding of ATAI Life Sciences N.V’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.02 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Needham on October 13, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On July 29, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $14.
H.C. Wainwright reiterated its Buy rating for the stock on November 18, 2024, while the target price for the stock was revised from $15 to $10.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 14 ’25 when Apeiron Investment Group Ltd. bought 8,675,799 shares for $2.19 per share. The transaction valued at 19,000,000 led to the insider holds 51,045,214 shares of the business.
SAHIL KIRPEKAR bought 83,332 shares of ATAI for $233,830 on Jul 02 ’25. On Jul 01 ’25, another insider, SAHIL KIRPEKAR, who serves as the Officer of the company, bought 106,093 shares for $2.77 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATAI now has a Market Capitalization of 1411075072 and an Enterprise Value of 1047666368. For the stock, the TTM Price-to-Sale (P/S) ratio is 4177.02 while its Price-to-Book (P/B) ratio in mrq is 7.80. Its current Enterprise Value per Revenue stands at 453.732 whereas that against EBITDA is -11.046.
Stock Price History:
The Beta on a monthly basis for ATAI is 1.60, which has changed by 3.5338984 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, ATAI has reached a high of $6.75, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 0.57%, while the 200-Day Moving Average is calculated to be 77.05%.
Shares Statistics:
For the past three months, ATAI has traded an average of 6.05M shares per day and 5634570 over the past ten days. A total of 212.24M shares are outstanding, with a floating share count of 174.80M. Insiders hold about 33.04% of the company’s shares, while institutions hold 10.44% stake in the company. Shares short for ATAI as of 1760486400 were 16124503 with a Short Ratio of 2.67, compared to 1757894400 on 17794037. Therefore, it implies a Short% of Shares Outstanding of 16124503 and a Short% of Float of 8.75.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of ATAI Life Sciences N.V (ATAI) in the stock market.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.09 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.43 and -$0.58 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.44, with 7.0 analysts recommending between -$0.28 and -$0.9.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for ATAI’s current fiscal year. The highest revenue estimate was $3.8M, while the lowest revenue estimate was $2.1M, resulting in an average revenue estimate of $2.53M. In the same quarter a year ago, actual revenue was $308k
